Table 1.
Correlation between β1C Immunoreactivity and the Pathological Characteristics of the Tumors Under Study
| Pathological characteristic | β1C Immunoreactivity | ||||
|---|---|---|---|---|---|
| Total | <10% | 10–50% | >50% | P value | |
| All cases | 283 | 42 (14.8%) | 72 (25.4%) | 169 (59.7%) | |
| Tumor type | |||||
| Invasive ductal NOS | 227 | 38 (16.7%) | 58 (25.6%) | 131 (57.7%) | |
| Invasive lobular | 25 | 2 (8%) | 9 (36%) | 14 (56%) | |
| Other types | 31 | 2 (6.5%) | 5 (16.1%) | 24 (77.4%) | |
| Tumor grade | |||||
| G1 | 76 | 1 (1.3%) | 6 (7.9%) | 69 (90.8%) | |
| G2 | 96 | 15 (15.6%) | 24 (25%) | 57 (59.4%) | |
| G3 | 111 | 26 (23.4%) | 42 (37.8%) | 43 (38.7%) | P < 0.001 |
| pT classification | |||||
| pT1 (a,b,c) | 180 | 20 (11.1%) | 41 (22.8%) | 119 (66.1%) | |
| pT2-4 | 100 | 20 (20%) | 31 (31%) | 49 (49%) | P = 0.015 |
| Unknown | 3 | 2 | 0 | 1 | |
| Node status | |||||
| Negative | 118 | 18 (15.3%) | 21 (17.8%) | 79 (66.9%) | |
| Positive | 155 | 23 (14.8%) | 46 (29.7%) | 86 (55.5%) | P = 0.069 |
| Unknown | 3 | 2 | 0 | 1 | |
| Ki-67 immunostaining | |||||
| 1–9% | 59 | 2 (3.4%) | 6 (10.2%) | 51 (86.4%) | |
| 10–19% | 80 | 8 (10%) | 24 (30%) | 48 (60%) | |
| 20–29% | 59 | 10 (16.9%) | 8 (13.6%) | 41 (69.5%) | |
| 30–39% | 36 | 7 (19.4%) | 10 (27.8%) | 19 (52.8%) | |
| 40–49% | 17 | 2 (11.8%) | 11 (64.7%) | 4 (23.6%) | |
| 50% and more | 32 | 13 (40.6%) | 13 (40.6%) | 6 (18.8%) | P < 0.001 |
| ER status | |||||
| Negative | 83 | 24 (28.9%) | 26 (31.3%) | 33 (39.8%) | |
| Positive | 200 | 18 (9%) | 46 (23%) | 136 (68%) | P < 0.001 |
| PgR status | |||||
| Negative | 151 | 32 (21.2%) | 42 (27.8%) | 77 (51%) | |
| Positive | 132 | 10 (7.6%) | 30 (22.7%) | 92 (69.7%) | P < 0.001 |
Abbreviations: NOS, not otherwise specified; pT, tumor stage; ER, estrogen receptor; PgR, progesterone receptor.